Michael Barbella, Managing Editor05.21.21
Second Sight Medical Products Inc. has appointed two new members, Dr. Dean Baker and Alexandra Larson. Baker has also been appointed to the board's Audit Committee.
“We are honored and excited to add these two very talented individuals to our board,” said Gregg Williams, board chairman. “I have worked with both for many years and know they are the exact blend of talent and experience we need to move this company strongly forward in our mission to cure all forms of blindness.”
Baker serves on the Board of Directors of Nano Precision Medical and served on the Board of Directors of Advanced Bionics prior to its sale to Boston Scientific Corp. In addition, he was the founding director of the Alfred E. Mann Institute for Biomedical Engineering at USC, and served for nine years on the Board of Directors (including serving on compensation, audit, and governance committees) for Semtech, a publicly traded semiconductor company. He currently serves on the Board of Directors for Transonic Imaging, a medical imaging startup. Baker was also a vice president of Northrop Grumman for 16 years including overseeing a division with $1 billion in annual sales.
Larson is vice president and general counsel of Williams International, a privately-held designer and manufacturer in the aerospace and defense industry. Prior to Williams International, Larson was legal director and associate general counsel at Amcor, corporate counsel at Compuware Corporation, and an associate at Baker and McKenzie. Larson has also held positions with the New York Stock Exchange and U.S. Department of Justice, Antitrust Division.
On April 5, Nasdaq notified the company that it was not in compliance with the Audit Committee composition requirement and thus may be subject to delisting. The company believes the addition of Baker to the Audit Committee puts it back into compliance with Nasdaq rules regarding audit committee composition. Nasdaq also notified the company that due to Matt Pfeffer’s resignation as acting CEO within one year of his appointment, Pfeffer is independent and the company was in compliance with rules regarding director independence.
Second Sight Medical Products develops and markets implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals.
“We are honored and excited to add these two very talented individuals to our board,” said Gregg Williams, board chairman. “I have worked with both for many years and know they are the exact blend of talent and experience we need to move this company strongly forward in our mission to cure all forms of blindness.”
Baker serves on the Board of Directors of Nano Precision Medical and served on the Board of Directors of Advanced Bionics prior to its sale to Boston Scientific Corp. In addition, he was the founding director of the Alfred E. Mann Institute for Biomedical Engineering at USC, and served for nine years on the Board of Directors (including serving on compensation, audit, and governance committees) for Semtech, a publicly traded semiconductor company. He currently serves on the Board of Directors for Transonic Imaging, a medical imaging startup. Baker was also a vice president of Northrop Grumman for 16 years including overseeing a division with $1 billion in annual sales.
Larson is vice president and general counsel of Williams International, a privately-held designer and manufacturer in the aerospace and defense industry. Prior to Williams International, Larson was legal director and associate general counsel at Amcor, corporate counsel at Compuware Corporation, and an associate at Baker and McKenzie. Larson has also held positions with the New York Stock Exchange and U.S. Department of Justice, Antitrust Division.
On April 5, Nasdaq notified the company that it was not in compliance with the Audit Committee composition requirement and thus may be subject to delisting. The company believes the addition of Baker to the Audit Committee puts it back into compliance with Nasdaq rules regarding audit committee composition. Nasdaq also notified the company that due to Matt Pfeffer’s resignation as acting CEO within one year of his appointment, Pfeffer is independent and the company was in compliance with rules regarding director independence.
Second Sight Medical Products develops and markets implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals.